Moxifloxacin

• 

  Subject Areas on Research

  • Association between cytotoxic and invasive Pseudomonas aeruginosa and clinical outcomes in bacterial keratitis. 
  • Detection of QT prolongation using a novel electrocardiographic analysis algorithm applying intelligent automation: prospective blinded evaluation using the Cardiac Safety Research Consortium electrocardiographic database. 
  • Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. 
  • Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India. 
  • Epithelial wound healing after cataract surgery comparing two different topical fluoroquinolones. 
  • Glucose homeostasis abnormalities associated with use of gatifloxacin. 
  • In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. 
  • Moxifloxacin-induced torsades de pointes. 
  • Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. 
  • Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis. 
  • Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. 
  • Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. 
  • Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. 
  • Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.